p63, cellular senescence and tumor development by Guo,  X. C. & Mills,  A. A.
©2
007
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
[Cell Cycle 6:3, 305-311, 1 February 2007]; ©2007 Landes Bioscience
Spotlight on p63 
p63, Cellular Senescence and Tumor Development
Xuecui Guo
Alea A. Mills*
Cold Spring Harbor Labratory; Cold Spring Harbor, New York USA
*Correspondence to: Alea A. Mills; Cold Spring Harbor Laboratory; Cold Spring 
Harbor, New York 11724 USA; Tel.: 516.367.6910; Fax: 516.367.8874; Email: 
mills@cshl.edu
Original manuscript submitted: 12/01/06
Manuscript accepted: 01/03/07
Previously published online as a Cell Cycle E-publication:
http://www.landesbioscience.com/journals/cc/abstract.php?id=3794 
Key words
p63, senescence, tumorigenesis, oncogene, 
tumor suppressor, animal model
AcKnowledGeMents
We would like to thank Dr. Bill Keyes and Dr. 
Peter Adams for their helpful discussion and 
critical reading of this review.
AbstrAct
Deficiency of p63, a p53-related protein, causes severe defects in epithelial morpho-
genesis. Studies of p63-compromised mouse models reveal that p63 deficiency induces 
cellular senescence both in cultured cells and in vivo, through regulation p19Arf/p53 and 
p16Ink4a/Rb pathways. An extensive tumor study of p63-compromised mice demonstrated 
that p63 deficiency does not predispose to, but rather protects from, tumor development. 
These findings further implicate p63 as a negative regulator of the tumor suppressive 
mechanism of cellular senescence. 
IntroductIon
Senescence is an essentially irreversible form of cell cycle arrest. The term “replicative 
senescence” was first coined by Hayflick and colleagues to describe the limited replication 
capacity of human diploid cells in culture.1 Subsequent studies revealed that senescence 
can be triggered in response to telomere attrition.2 Stress stimuli such as DNA damage 
and oncogenic signals can induce a similar phenomenon referred to as premature senes-
cence or oncogene-induced senescence.3 The term “cellular senescence” is commonly 
used to encompass both replicative and premature senescence. Senescent cells remain 
metabolically active, undergo morphological changes, become flattened and vacuolar, and 
exhibit senescence-associated β-galactosidase (SA-β-gal) activity at acidic pH.4 The tumor 
suppressors p53, p16Ink4a and promyelocytic leukemia protein (PML) are up-regulated in 
senescent cells.3,5-7 
Recent work from our laboratory has determined that deficiency of p63 induces senes-
cence.8 p63 belongs to the p53 family of proteins that in addition to p53, also includes p73. 
p63 encodes at least six different proteins due to multiple promoter usage and alternative 
splicing.9 Isoforms with an N-terminal transactivation domain homologous to that of p53 
are referred to as the TA isoforms, whereas isoforms lacking this domain are referred to 
as the ΔN isoforms.9 There is significant structural homology between p63 and p53 in 
the transactivation-, DNA binding- and oligomerization domains, suggesting that p63 
shares functional similarities with p53.9 Indeed, p63 binds to p53-responsive elements and 
transactivates a number of p53 target genes such as p21, Bax, Perp.9-12 Like p53, p63 can 
induce apoptosis.9,10,13,14 However, in contrast to the majority of p53 deficient mice that 
develop normally and are viable,15 p63 deficient mice have severe developmental defects 
affecting the skin and limbs that cause them to die shortly after birth.16,17 In addition, 
whereas p53 heterozygous mutant mice are highly tumor-prone,15,18 mice heterozygous 
for inactivated p63 alleles are either tumor-resistant19 or develop very few tumors.20 
Moreover, p63 heterozygotes have a shortened lifespan and exhibit features of accelerated 
aging.8 To bypass the embryonic lethality imposed by complete absence of p63 throughout 
the embryo, a novel p63 conditional mouse model was developed, providing a system for 
studying the role of p63 at later stages.21 Indeed, this p63 conditional model implicates 
p63 as a regulator of cellular senescence, thereby providing a link between cellular senes-
cence and aging in vivo.8 The finding that p63 deficiency induces cellular senescence 
suggests a potential mechanism for the decreased tumor incidence in p63-compromised 
mice. The validity of this hypothesis however, awaits further investigation.
p63 Is A MedIAtor of cellulAr senescence And AGInG
The decreased life span and the striking age-related decline observed in p63 heterozy-
gous mutant mice are consistent with the ability of p63 deficiency to induce senescence.8 
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In support of the hypothesis that p63 modulates organismal aging, 
high levels of endogenous SA-β-gal activity, a marker of senescent 
cells, was detected in p63 deficient embryos. This augmented SA-β-gal 
activity was also observed when p63 was ablated somatically. Indeed, 
Cre-mediated p63 disruption specifically in proliferative cells of 
stratified epithelia such as the skin during midgestation induced 
cellular senescence. Immunofluorescence analysis indicated that the 
expression of additional senescence markers p16 and PML increased 
significantly in embryos rendered p63 deficient either in the germ-
line or in somatic tissues. Markers of cellular senescence were also 
induced when p63 was ablated in proliferating keratinocytes of adult 
mice at 8 months of age. Interestingly, induced p63 deficiency caused 
features of accelerated aging, a phenotype that is somewhat similar to 
that caused by elevated p53 activity.22,23 These studies suggest a caus-
ative link between cellular senescence and aging in vivo. Senescence 
induced in response to Cre-mediated p63 ablation was also confirmed 
in primary keratinocytes in culture. Thus, p63 deficiency can evoke 
cellular senescence both in vivo and in cultured cells.
A separate study also implicates p63 as a regulator of aging. The 
Sidransky group reported that transgenic mice that express ΔNp63α 
under the control of keratin14 (K14) promoter displayed an aging 
phenotype in vivo.24 The authors observed an inverse correlation 
between expression of the K14-ΔNp63α transgene and expression 
of SIRT1, a histone deacetylase that can inhibit PML/p53-mediated 
cellular senescence.25 It is surprising that the seemingly opposing 
approaches of loss- and gain of p63 function both led to the conclusion 
that p63 is a modulator of the aging process. It would be interesting to 
understand the mechanism whereby exogenous expression of a single 
p63 isoform causes a similar effect as loss of all the p63 isoforms.
p63-reGulAted MoleculAr pAthwAys In the senescent 
process
Cellular senescence can be induced by a variety of stimuli such 
as DNA damage, shortening of telomeres, over-expression of onco-
genes, and chromatin modification.26 Irrespective of the diverse 
stimuli that converge to regulate cellular senescence, this program 
mainly involves p19Arf/p53 and p16Ink4a/Rb, the two major tumor 
suppressor pathways. These pathways play a key role during the 
induction and the maintenance of senescence.26,27 Molecules that 
regulate these pathways may also regulate the senescent pathway.
p63 and the Arf/p53 pathway. p53 is a key regulator of the 
senescence response to DNA damage, oncogenic signals and many 
other stimuli, and its downstream target gene p21 has been proposed 
to encode a major regulator of cell cycle arrest during the senescent 
process.26,27 The functional interaction between p53 and p63 has 
been well documented. For example, p63 interferes with p53's 
transcriptional activity.9 p63 can inhibit the expression of a number 
of p53 target genes, and thus p63 may counteract p53 activity, at 
least partly by competing for p53 consensus DNA binding sites.9 
On the other hand, p53 interacts directly with ΔNp63α to mediate 
its proteasomal degradation.28 Induction of apoptosis in primary 
keratinocytes in response to ultraviolet (UV) light simultaneously 
stabilizes p53 and decreases ΔNp63α levels, the predominant 
isoform in proliferating epidermal keratinocytes.29 Forced expression 
of ΔNp63α in the epidermis can inhibit UV-induced apoptosis.29 
Given these close physical and functional interactions between p53 
and p63, it is tempting to speculate that both senescence and aging 
induced by enhanced p53 activity involves a compromise in p63 
activity. Indeed, p63 deficiency evokes cellular senescence in vivo, and 
this phenotype is retained in a p53 deficient background, suggesting 
that p63 functions either downstream or in parallel with p53.8,30 
In cultured primary keratinocytes, RNAi-mediated knockdown of 
p53 bypasses senescence induced by p63 ablation, indicating that 
p63 functions upstream of p53 during the senescent process. It will 
be interesting to determine whether these findings reflect a negative 
feedback loop between p63 and p53.
Recently, the insulin and insulin-like growth factor 1 (IGF-1)-
signaling pathway has been linked to organismal aging. Mutations 
that inhibit this signaling pathway significantly extend the life 
span of many species.31,32 This evolutionarily conserved pathway is 
induced by the N-terminally truncated p53 isoform p44. The enhanced 
IGF-1 signaling sustains p21 expression through the Ras-MAP kinase 
pathway, thus contributing to the decreased proliferation, increased 
cellular senescence and accelerated aging phenotypes.23 Interestingly, 
p63 inhibits the expression of both the IGF-1 receptor and the 
IGF binding protein IGFBP3,33,34 two important components of 
the insulin/IGF-1 axis. Thus, an enhanced insulin/IGF-1 signaling 
caused by loss of p63 might mediate senescence. Furthermore, 
previous work demonstrates that TAp63 up-regulates9,35-38 while 
ΔNp63α represses,39 transcription of p21. Future studies should 
determine whether p21 is induced in senescent tissues of p63 
deficient mice.
Another mechanism by which p63 might regulate cellular senes-
cence is through regulating the activity of Arf (p14Arf in human, 
p19Arf in mouse), an upstream negative regulator of Mdm2. Mdm2 
is a negative regulator of p53, therefore p19Arf facilitates p53 
function. It was shown that Arf interacts with p63 and inhibits 
its transcriptional activity, indicating that these two proteins are 
physically and functionally connected.40 However, the authors also 
observed that overexpression of TAp63 isoforms (but not ΔNp63 
isoforms) can relocalize Arf from nucleoli to nucleoplasm.40 Thus, 
TAp63 may interfere with the normal function of this nucleolar 
protein, suggesting that p63 has a negative effect on Arf and that 
reduced p63 expression enhances Arf/p53 function.
p63 and the p16/Rb pathway. The second critical medi-
ator of senescence induction and maintenance is the p16Ink4a/Rb 
pathway.26,27 The requirement of p16Ink4a/Rb pathway for the 
formation of senescence-associated heterochromatic foci (SAHF), 
which may keep pro-proliferative genes in a repressed state, provides 
a molecular mechanism underlying p16Ink4a/Rb regulation of 
senescence.7 In our study,8 p16 was dramatically upregulated in 
p63-ablated tissues in vivo, suggesting that p63 functions upstream 
of the p16Ink4a/Rb pathway in the senescent process. Interestingly, 
crosstalk between the p19Arf/p53 and p16Ink4a/Rb pathways has 
been suggested through p21. This involves the hypophosphorylation 
and activation of Rb through p21-mediated inhibition of Cyclin E-
Cdk2.26,41 As mentioned above, the TAp63- and ΔNp63 isoforms 
regulate p21 expression in a positive and negative manner, respec-
tively. Thus, it is likely that p63 regulates the p16Ink4a/Rb senescence 
pathway through regulation of p16Ink4a and p21 expression (Fig. 1).
p63 and PML. PML was originally discovered based on its role 
in the pathogenesis of acute promyelocytic leukemia, and later was 
found to play an essential role in cellular senescence and tumor 
suppression.42-44 Keyes et al. found an increase in PML expression 
in p63-deficient cells, and that both the size and number of PML 
nuclear bodies was enhanced by p63 loss.8 Functionally, knockdown 
of PML in primary keratinocytes by PML-specific short hairpins 
abolished the induction of cellular senescence, implicating PML 
in p63-deficiency induced cellular senescence. These data also 
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suggest that p63 is an upstream suppressor of PML. The molecular 
mechanism for p63-mediated regulation of PML remains unknown. 
In contrast to these studies that place PML downstream of p63, 
Bernassola et al11 reported that PML interacts with p63, potentially 
through p63’s DNA binding domain, and that over-expression of 
PML increases p63 accumulation at least partially by inhibiting 
ubiquitination of p63. In addition, PML regulates TAp63 transcrip-
tional activity, suggesting a regulatory feedback loop between p63 
and PML. PML interacts with and enhances p53’s transactivation 
activity42 and p53 is also a direct transcriptional activator of the 
PML promoter.45 Based on the high sequence homology between 
p53 and p63, it is very likely that p63 can directly bind to PML and 
also inhibit expression of PML at the transcript level. Given the fact 
that there are at least six isoforms of p63, and each has potentially 
different, even opposing functions, further studies will be required to 
elucidate the reciprocal regulation between p63 and PML. 
PML can be upregulated by oncogenic Ras. It directly interacts 
with the DNA binding domain of p53 and regulates the acetylation 
of p53 through acetyltransferase CBP/p300 in the PML-NBs, thereby 
inducing cellular senescence.42,43 PML was also shown to enhance 
the stability of p53 by inhibiting Mdm2 function.46 Moreover, 
PML can interact with Rb, thereby promoting Rb’s transcriptional 
repression activity.47 Given the role of PML in tumor suppression44 
and the reciprocal regulation between PML and p63, it is very likely 
that p63 interferes with oncogene-induced cellular senescence 
by regulating PML. Notably, a recent study implies a critical role 
of PML bodies in SAHF formation.48 Given the report that p63 
colocalizes with PML in PML bodies,11 it would be interesting to 
determine the role of p63 in SAHF formation during senescence.
the pro-prolIferAtIon or pro-survIvAl property of p63
Consistent with the induction of senescence that is mediated by 
deficiency of p63, an extensive body of evidence demonstrates p63’s 
striking pro-proliferative or pro-survival function. These studies 
suggest a number of potential pathways that p63 regulates to modu-
late these processes. It was shown that overexpression of ΔNp63α 
in Rat 1a cells enhances growth in soft agar and increases tumor 
volume in nude mice.49 A DNA microarray gene expression profile 
in Saos-2 cells showed that ΔNp63, but not TAp63, up-regulates 
Hsp70, a gene that is actively involved in inhibition of apoptosis 
and enhancement of survival.50 Furthermore, Wu et al. found that 
ΔNp63α transactivates Hsp70 expression by direct interaction with 
the CCAAT binding factor.51 On the other hand, ΔNp63α can also 
bind to the regulatory regions of genes encoding cell cycle inhibitors 
p21 and 14-3-3σ to repress their transcription.39 The expression of 
ΔNp63α is induced by epidermal growth factor activation through 
phosphoinositide 3-kinase (PI3K) pathway,52 which is a potent 
pro-survival and pro-proliferation factor in mammalian cells.53 The 
report that ΔNp63α is a downstream target of PI3K implies that 
ΔNp63α is an important player in cell proliferation and survival. 
Recently, over-expression of ΔNp63α in squamous cell carcinoma 
cells was shown to promote cell survival in a p53-independent 
manner by interfering TAp73β-regulated transactivation of the 
proapoptotic genes Puma and Noxa.54
ΔNp63α has also been linked to glycogen synthase kinase 3β 
(GSK3β) and the β-catenin pathway.55 ΔNp63 binds to GSK3β 
and the regulatory subunit of protein phosphotase PP2A, leading to 
the inhibition of GSK3β reactivation, and subsequently decreased 
phosphorylation and nuclear accumulation of β-catenin.55 Increased 
nuclear β-catenin has been heavily implicated in human cancers. The 
ability of p63 to mediate β-catenin signaling provides a molecular 
basis for the oncogenic function of p63. p63’s regulation of GSK3β 
activity may provide an important clue as to a mechanism whereby 
p63 deficiency causes cellular senescence. Given the evidence that 
GSK3β accumulates in the nucleus of senescent human fibroblasts,56 
and the fact that p53 activity can be regulated through serine phos-
phorylation by GSK3β,57 it is possible that p63 loss increases GSK3β 
activity and subsequently enhances p53 activity. Most interestingly, 
recent work from the Adams group showed that GSK3β interacts 
with and phosphorylates chromatin regulator HIRA, which leads 
to the translocation of the phosphorylated HIRA to PML bodies 
and an increase in SAHF formation (Personal communication, Peter 
Adams). It would be interesting to determine whether p63 deficiency 
enhances GSK3β activity, thus increasing HIRA phosphorylation, 
induction of SAHF formation and senescence (Fig. 1). 
The tumor-related pro-proliferative function of ΔNp63 has also 
been reported for TAp63 isoforms. Upregulation of TAp63 isoforms 
at the transcript level was recently reported in human squamous 
cell carcinomas.58 Koster et al. found that targeted overexpression 
of TAp63α in the basal layer of the epidermis caused widespread 
hyperproliferation and severe hyperplasia at the cost of epidermal 
differentiation.59 A report from the same laboratory recently demon-
strated that TAp63α expression is frequently enhanced in the 
majority of human well-differentiated head and neck squamous cell 
carcinomas (HNSCC).60 Furthermore, over-expression of TAp63α 
in the epidermis promoted chemical tumorigenesis and malignant 
progression. A correlation between TAp63 expression and epithe-
lial-mesenchymal transition (EMT) and EMT regulators Twist and 
N-cadherin was also shown. However, p63’s involvement in EMT 
has not been reported.
Recently, Sbisa et al. reported that both TAp63α and ΔNp63α 
promote cellular proliferation by direct transactivation of adenosine 
deaminase (ADA) and that TAp63α is the p63 isoform that has the 
most profound effect in this process.61 These findings suggest that 
p63 can promote tumor development not only by counteracting p53 
activity, but also by directly controlling the expression of proliferative 
genes. Interestingly, enhanced expression of TAp63 isoforms was not 
Figure 1. p63 deficiency induces cellular senescence. p63 deficiency 
induces the expression p16Ink4a and PML.8 The enhanced p16Ink4a and PML 
promote SAHF formation and senescence. Given the finding that ΔNp63α 
inhibits GSK3β activity,55 p63 deficiency potentially enhances GSK3β activ-
ity. The increased activity of GSK3β can regulate p53 and the chromatin 
regulator HIRA, thus regulating senescence. On the other hand, p63 can 
inhibit the transactivation of cell cycle inhibitors p21.39 Thus, p63 deficiency 
can cause upregulation of p21. p21 has been proposed to be a key effector 
of p53-mediated senescence by inhibiting Cyclin E-Cdk2.26 
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only seen in epithelial tissues, but was also observed in non-epithe-
lial tumors such as lymphomas.62-66 The role of enhanced TAp63 
activity in lymphomagenesis remains to be investigated. 
These studies suggest a potential oncogenic role for p63 when 
it is over-expressed (Fig. 2). The consequences of loss of such a 
potent pro-proliferation or pro-survival gene in normal or cancerous 
cells could be either apoptosis or cellular senescence, depending 
on the specific cellular context. Indeed, senescence was induced 
in primary keratinocytes both in cultured cells and in vivo when 
p63 was ablated.8 Consistent with senescence induction induced 
by p63 loss, Sbisa and colleagues observed that knockdown of p63 
using siRNAs reduced ADA expression concomitant with decreased 
cellular proliferation.61 In human squamous cell carcinoma cells, 
apoptosis is the main consequence of shRNA-mediated knockdown 
of p63.67 Although the molecular mechanism underlying a cell’s 
choice between apoptosis and senescence is not thoroughly under-
stood, regulation of these tumor suppressive responses is likely to 
have important implications for anticancer therapies.
p63 And tuMor developMent
Although p63 shares significant sequence similarity and protein 
domain conservation with p53, there is strong evidence supporting 
an oncogenic role for p63 in tumorigenesis, whereas p53 is a 
classic tumor suppressor. In contrast to p53 that is highly mutated 
in the majority of human tumors,68 p63 is rarely mutated.69 A 
thorough analysis of p63 expression in primary esophageal tumors 
conducted by Cui et al58 demonstrated that p63 is often upregulated 
at the transcript level in human tumors with a predominance of 
enhanced ΔNp63α expression at the protein level. The p63 locus 
is frequently amplified in squamous cell carcinoma of the lung and 
head and neck.49,70 Even though p63 expression appears to be most 
pronounced in epithelial tissues, enhanced expression of p63 is also 
found in human hematopoietic malignances such as diffuse large B 
cell lymphoma (DLBCL) and follicular lymphoma (FL). 
p53 heterozygous- or homozygous mutant mice are highly tumor-
prone.15,18 The homology between p53 and p63 originally suggested 
a tumor suppressive function for p63. To assess the impact of p63 
deficiency on tumorigenesis in an intact organism, we performed 
an extensive spontaneous and chemical-induced tumor study on a 
large cohort of p63 heterozygous mutant mice.19 We found that 
p63+/- mice are not prone to spontaneous tumor development, but 
often develop non-malignant pathology. Moreover, p53+/- and p63+/- 
compound mice had fewer tumors than p53+/- mice. Surprisingly, 
p63-comprised mice are not susceptible to chemically-induced 
tumorigenesis, even though p63 plays an essential role in the devel-
opment and homeostasis of the epidemis. These observations indicate 
that p63 does not function as a tumor suppressor in a manner similar 
to p53, rather, that decreased p63 expression could be tumor protec-
tive.19,71 Using the same p63 deficient model, Perez-Losada et al. 
demonstrated that p63 did not show tumor suppressive function in 
irradiation-induced lymphomagenesis.72 Consistent with the Keyes 
study,19 this report demonstrated that combined p53 and p63 defi-
ciency did not enhance irradiation-induced lymphomagenesis. These 
findings are consistent with reports in the literature demonstrating 
that p63 is upregulated in human tumors, strongly supporting an 
oncogenic, rather than a tumor suppressive, role for p63. 
An independent study of spontaneous tumors in p63+/- mice 
using a different p63 mouse model reported a tumor predisposition, 
suggesting a tumor suppressor function for p63.20 The different 
conclusions drawn from the Flores and the Keyes studies could be 
due to the distinct p63 alleles that were generated in the two different 
p63 mouse models.16,17,19,20 Notably however, there is some consis-
tency in the tumor incidence from the two different p63 models.19,20 
Both p63 deficient models displayed shortened life span, features 
of aging and a high incidence of premalignant hyperplasia. When 
compared to p53 heterozygous mutant mice, both studies observed a 
decreased tumor incidence of lymphomas and sarcomas in p63+/- and 
p63+/-;p53+/- compound mutant mice. These observations suggest 
that at least in these types of tumors, haploid levels of p63 does not 
promote tumor development, but rather is potentially protective. 
Senescence has long been proposed to interfere with tumor 
development.3 However, only recently has the senescence program 
been shown to prevent tumor progression in premalignant lesions 
in vivo.73-77 With regards to the findings that p63 deficiency causes 
cellular senescence, it is intriguing to speculate that loss of p63 
decreases tumor incidence by activating the senescence program. 
Given the high incidence of hyperplasia in p63 compromised mice, 
it would be interesting to determine whether senescence induction 
occurs in premalignant lesions such as in lung adenomas and squa-
mous cell hyperplasia. The ability of cellular senescence to decrease 
tumor incidence in p63 compromised mice and the isoform-specific 
effects of p63 on induction and maintenance of senescence remain 
to be elucidated. 
The role of p63 in tumorigenesis so far manifests high complexity. 
In addition to the evidence supporting an oncogenic role for 
p63, a tumor suppressive function of p63 has also been proposed. 
Indeed, both p53 and p63 can be induced following DNA damage. 
Functionally, p63 can exhibit p53-like activity in both binding and 
transactivation of certain p53 target genes, such as Bax, Perp and 
Noxa, Pig3 and p21—genes encoding proteins involved in the execu-
tion of apoptosis or cell cycle arrest. Over-expression of TAp63α or 
TA63γ was shown to be able to induce apoptosis in certain types of 
cells.9,10,14 p63, together with p73, is required for p53 to bind and 
activate certain apoptosis-related genes, and p53 mutants derived 
from human cancers interact with p63α and reduce p63α-mediated 
growth inhibition in Saos-2 cells.78 There is also evidence showing 
that loss of p63 occurs in certain types of human cancers. Whether 
Figure 2. ΔNp63α promotes cellular proliferation. ΔNp63α can inhibit 
GSK3β activity through interacting with and inhibiting the protein phospho-
tase PP2A. The decreased GSK3β activity leads to β-catenin nuclear accu-
mulation, thus its pro-proliferative function.55 ΔNp63α is induced by EGF 
through the PI3K pathway.52 ΔNp63α can promote cellular proliferation by 
inducing oncogenic proteins such as Hsp70.51 On the other hand, ΔNp63α 
can inhibit the activity of p539 and the transactivation of cell cycle inhibitors 
such as p21 and14-3-3σ,39 thus enhancing cellular proliferation.
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this decreased expression is a consequence of a switch to a mesen-
chymal cell type (e.g. during the process of EMT that frequently 
occurs in tumors derived from epithelial tissues), rather than from 
p63 loss, per se, awaits further investigation. These studies suggest 
that p63 is involved in apoptosis and cell cycle arrest, and that some 
isoforms may function as tumor suppressors. Thus, whether p63 
functions as tumor suppressive gene or oncogene in tumor develop-
ment is still controversial.71
An IsoforM- And cellulAr conteXt-specIfIc Issue 
TAp63 and ΔNp63 are not only likely to be regulated differen-
tially in response to certain stimuli,79,80 but these different isoform 
classes probably also regulate sets of genes that have completely 
distinct biological functions.50 It is very likely that there are cell-
type specific functions for different isoforms of p63. For example, 
TAp63α has been shown to induce apoptosis in Hep3B and Saos2 
cells through affecting both the intrinsic and extrinsic apoptosis path-
ways.10 However, this effect of TAp63α was not observed in BHK 
cells.9 Although p63 was shown to be required for p53 to induce 
apoptosis in E1A-expressing mouse embryonic fibroblasts (mefs),13 
loss of p63 in primary thymocytes does not interfere with either 
p53-dependent or p53-independent apoptosis.81 Also, as specifi-
cally demonstrated by Jacobs et al,14 developing neurons express 
only full length TAp63 isoforms, and TAp63γ promotes apoptosis 
during neural development, consistent with the observation by 
Flores and colleagues that loss of p63 confers partial resistance to 
irradiation-induced apoptosis in the developing nervous system.13 
In murine keratinocytes, where ΔNp63α is the dominant isoform, 
ablation of p63 induces cellular senescence.8 In contrast, shRNA-mediated 
inhibition of p63 induces apoptosis in HNSCC cell lines.54 Although 
over-expression of ΔNp63α promotes survival in HNSCC,54 an 
apoptosis-inducing activity of ΔNp63α was demonstrated in non-
small cell lung carcinoma cell line H1299.38,82 Another example for 
cellular context issue is TAp63α: it promotes proliferation in mouse 
epidermis,60 while it induces apoptosis in Hep3B cells.10 We found 
that exogenous expression of either isoform of p63 did not induce 
apoptosis in wild type mefs or immortalized NIH 3T3 cells (Guo 
and Mills, unpublished data). Thus, the tissue specific consequence 
of p63 isoform expression is evident.
The interplay among the p53 family members and among the p63 
isoforms further complicates the net effect of p63 in specific cellular 
circumstances. Interactions have been found between p53 family 
members.9,54,78 For example, p53 not only negatively regulates p63 
expression,83,84 but also interacts with and targets p63 for protea-
somal degradation.28 On the other hand, p63 interacts with the p53 
response elements and interferes with p53’s transactivation activity.9 
Recently, ΔNp63α was found to promote tumor cell survival by 
inhibiting TAp73β-dependent transactivation of proapoptotic genes 
in a p53-independent manner.54 The interplay between p63 isoforms 
was also demonstrated. As shown by Yang et al., ΔNp63 not only 
interferes with p53, but also with TAp63 isoforms to inhibit their 
transactivation function.9 On the other hand, TAp63 isoforms can 
regulate the expression of ΔNp63 isoforms.67,85 Two recent studies 
reported the presence of p63 binding sites in the p63 gene itself,83,84 
suggesting that ΔNp63 is transcriptionally regulated by TAp63. 
Recently, a keratinocyte-specific enhancer element was found in the 
fourth intron of the p63 gene.86 This enhancer requires p63 but not 
p53 for appropriate regulation of p63, thus creating an autoregula-
tory loop. Interestingly, ΔNp63α and ΔNp63γ exert opposing effects 
via this cis acting control element, with ΔNp63γ enhancing and 
ΔNp63α inhibiting the expression of endogenous p63.86 
Thus, different isoforms of p63 can be involved in different 
biological events; a given isoform can function differently in a 
specific cell type and in a specific cellular context. The net effects of 
p63 are probably determined by dominant expression of a specific 
isoform and the balance between the different isoforms of p63 and 
amongst additional members of the p53 family as well. The precise 
function of each p63 isoform in primary wild-type cells including 
epithelial cells and non-epithelial cells and in tumorigenesis needs 
to be more fully characterized using genetic approaches. The p63 
deficient mouse models generated to date presumably interfere with 
the expression of all the isoforms,16,17,21 so that it is not possible to 
dissect the specific functions for each isoform using these models. 
Thus, isoform-specific knockout or conditional models will certainly 
be crucial for addressing this issue in an in vivo setting. In order 
to make isoform-specific knockout models, exons specific for the 
TAp63 isoforms can be deleted, generating a TAp63 deficient mouse 
model. Similarly, an exon that is specific for ΔNp63 isoforms can 
be deleted, generating the ΔNp63 deficient mouse model. With the 
generation of isoforms-specific models, the role of TA- or ΔNp63 in 
the tumor development and aging will certainly be clarified in the 
context of the whole organism. 
In summary, p63 regulates a number of pathways to form a 
complex molecular network, and the number of isoforms adds even 
further complexity to this system. p63 could serve as an oncogene 
during tumorigenesis, either by facilitating the expression of pro-
proliferative genes such as Hsp70 or by the inhibition of expression 
of proliferation regulatory genes such as p21 and GSK3β kinase (Fig. 
2). On the other hand, p63 deficiency can induce cell cycle arrest 
and/or senescence by regulating p16, PML, p21 and GSK3β. The 
senescence program activated by loss of oncogenic p63 is a potential 
barrier for tumor development that may be able to be exploited to 
design more effective anticancer therapies.
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